Charles River Laboratories Intl. Inc vs GXO Logistics Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while GXO Logistics Inc trades at $46.63 (market cap $5.32B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 2.7× GXO Logistics Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, GXO Logistics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and GXO Logistics Inc for 28 Days on average.
| CRL | GXO | |
|---|---|---|
Market Cap | $14.23B | $5.32B |
Volume | 1,176,885 | 1,255,816 |
Sector | Health | Industrials |
52-Week High | $310.77 | $65.59 |
52-Week Low | $149.93 | $44.17 |
Typical Hold Time | 33 Days | 28 Days |
Enterprise Value | $17.06B | $10.67B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
GXO trades at $46.47, up 1.04% with neutral technical indicators and strong analyst support. The company shows improving fundamentals with Q2 2026 revenue of $3.4 billion (up 4% YoY) and three consecutive earnings beats. Recent strategic partnerships with Columbia Sportswear and technology investments in labor management systems position GXO for operational efficiency gains. The stock trades at a P/E of 41.03 and P/S of 0.39, reflecting growth expectations amid modest current profitability.
GXO presents a compelling growth story with 88.9% analyst buy ratings and a $66.67 consensus price target (43% upside). However, margin compression remains a concern as new business wins show lower incremental profitability. The company's expansion in aerospace/defense and European logistics markets provides growth catalysts, but investors should monitor execution on the 6% EBIT margin target and supply chain industry headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →GXO is the world's largest pure-play contract logistics provider. It offers cutting-edge supply chain solutions, including automated warehousing and fulfillment, for global blue-chip companies.
Read more on GXO →